Celldex Therapeutics (CLDX) Liabilities and Shareholders Equity (2010 - 2026)

Celldex Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $511.3 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 30.86% year-over-year to $511.3 million; the TTM figure through Mar 2026 stood at $2.4 billion (down 23.92% YoY), while the FY2025 annual figure was $583.0 million, down 26.42% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $511.3 million, down from $583.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $868.8 million in Q1 2024, with the low at $280.3 million in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $511.3 million (2026), against an average of $554.3 million.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity jumped 193.72% in 2024, then slumped 30.86% in 2026.
• Celldex Therapeutics' Liabilities and Shareholders Equity stood at $352.7 million in 2022, then surged by 32.0% to $465.6 million in 2023, then surged by 70.17% to $792.3 million in 2024, then retreated by 26.42% to $583.0 million in 2025, then fell by 12.3% to $511.3 million in 2026.
• Business Quant data shows CLDX's Liabilities and Shareholders Equity at $511.3 million in Q1 2026, $583.0 million in Q4 2025, and $648.4 million in Q3 2025.